CTRI/2025/05/087476尚未招募3 期
Cannabidiol Adjunctive Therapy for Acute Bipolar Depression: A Randomized Double-Blind, Placebo Controlled Trial
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 360
- 试验地点
- 4
- 主要终点
- Improvement in depressive symptoms, as measured by changes in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from baseline to week 6.
研究概览
简要总结
It is a randomized controlled trial comparing cannabidiol vs placebo as an add-on treatment for patients with bipolar disorder, who are currently in a depressive episode and have not responded to an adequate first line treatment. The primary objective of the study is to assess the efficacy, safety and tolerability of adjunctive CBD vs placebo in patients with acute bipolar depression (BD I or BD II) who have not responded to adequate trials with at least one first-line treatment outlined in the most recent CANMAT clinical guidelines for bipolar I disorder (i.e. lithium, quetiapine, lamotrigine, or lurasidone), or at least one first or second-line treatment for bipolar II depression (i.e. quetiapine, lithium, lamotrigine, sertraline, or venlafaxine as monotherapy or adjunctive therapy, or bupropion adjunctive therapy). We plan to recruit 360 study participants globally over 5 years, who will be randomly allocated to receive either cannabidiol or placebo (1:1 ratio) for a period of 6 weeks. The primary efficacy measure for the study is improvement in depressive symptoms, as measured by changes in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from baseline to week 6. In addition to periodic structured clinical assessments, the study participants would undergo blood investigations to evaluate biomarkers (multi-omics, cytokines, oxidative stress markers, neurotropins) of treatment response and measure cannabidiol levels at screening and at the end of the study period (6 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Permuted block randomization, variable
- 盲法
- Participant, Investigator and Outcome Assessor Blinded
入排标准
- 年龄范围
- 19.00 Year(s) 至 70.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Males or females aged 19 to 70 years (inclusive).
- •2.DSM-5 diagnosis of BD I or BD II, AND a current major depressive episode confirmed by MINI 7.0.2 .
- •3.All patients must be taking either a mood stabilizer (i.e. lithium or valproate; lamotrigine monotherapy as a mood stabilizer is acceptable for BD II patients only and not for BD I) OR an atypical antipsychotic OR a combination of these (two mood stabilizers or a mood stabilizer plus an atypical antipsychotic), at therapeutic doses.
- •Medications and therapeutic doses are: lithium, serum level 0.6 to 1.2 mEqL; divalproex/sodium valproate, serum level 350 to 700 uML(45 to 125 mcgml); risperidone 2 to6 mg/day; olanzapine 5 to 30 mg/day; quetiapine IR or XR 300 to 900 mg/day; aripiprazole 10 to 30 mg/day; and ziprasidone 80-160 mg/day.
- •Combinations of these medications as outlined above, or the combination of any of them with lamotrigine 100400 mg daily, or the combination of a mood stabilizer plus asenapine 5 to 20 mg/day are also permitted.
- •4.Have received a minimum of 6-weeks treatment at adequate doses for treatment of current depressive episode with at least one CANMAT recommended first-line treatment for bipolar I disorder (i.e. lithium, lamotrigine, lurasidone, or quetiapine either as monotherapy or adjunctive therapy), or at least one first or second-line treatment for bipolar II depression (i.e. a.quetiapine, lithium, lamotrigine, sertraline, or venlafaxine as monotherapy or adjunctive therapy, or bupropion adjunctive therapy).
- •5.A MADRS score of greater than or equal to 20 and a YMRS score of less than or equal to 12 (these cut off scores are standard in bipolar depression RCTs).
- •6.Inpatient or outpatient status.
- •7.All participants are required to agree to practice highly effective methods of contraception (i.e. a.hormonal contraceptives, intrauterine device or system, vasectomy and tubal ligation, or double barrier methods of contraception) OR agree to completely abstain from heterosexual intercourse.
- •Females who do not have childbearing potential are required to be postmenopausal for at least 1 year before the screening visit (confirmed by an FSH test) OR surgically sterile.
- •8.The capability of understanding, consenting to and complying with study requirements.
- •9.All concomitant medication must be at a stable dose for two weeks prior to the randomization visit.
排除标准
- •1.Current depressive episode greater than 12 months.
- •2.A history of rapid cycling, defined as 4 or more mood episodes in the preceding 12 months.
- •3.Current unstable or inadequately treated medical illness with the exception of current depression.
- •4.Recently started taking a CANMAT-recommended treatment for the management of acute bipolar depressive episode, but has not had a trial for a minimum of 6 weeks with adequate doses.
- •5.Recently (i.e. within the past 8 weeks) began structured psychotherapy (i.e. cognitivebehavioral therapy, interpersonal psychotherapy, family-focused therapy, or interpersonal and social rhythm therapy).
- •6.Current use of stimulant medications.
- •7.A history of non-response or intolerance to CBD.
- •8.Current or past month daily use of CBD, or any product or drug that contains CBD.
- •Occasional users will be included if they agree to refrain from using during the trial.
- •10.A current diagnosis of other primary psychiatric disorders as assessed by a study investigator to be primary and causing greater impairment than BD.
- •11.A lifetime history of a primary psychotic disorder (e.g. schizoaffective disorder, bipolar subtype) according to DSM-5 criteria.
- •12.Patients who have met the DSM-5 criteria for a substance use disorder (except for nicotine or caffeine) within the past 6 months.
- •13.Significant active suicidal ideation (as evidenced by MADRS suicide item score of 4 for more).
- •14.Pregnancy or lactation.
- •15.Liver function tests (AST and ALT) three times the upper limit of normal.
结局指标
主要结局
Improvement in depressive symptoms, as measured by changes in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from baseline to week 6.
时间窗: week 6
次要结局
- anxiety symptoms scores measured objectively with the Hamilton Anxiety Rating Scale (HAM-A), and subjectively with the General Anxiety Disorder-7 (GAD-7) and State-Trait Anxiety Inventory (STAI)(week 6)
- Response rate(week 6)
- Remission rate(week 6)
- Treatment emergent manic/hypomanic events(Week 0- 6)
- changes in Hamilton Depression Rating Scale 21- item (HAM-D)(week 6)
- global severity of symptoms as indicated by changes in Clinical Global Impressions Scale, Bipolar Version, Severity (CGI-BP-S) and global improvement in symptoms with Clinical Global Impressions Scale, Bipolar Version, Change (CGI-BP-C)(week 6)
- subjective depressive symptoms as measured by changes in the Quick Inventory of Depressive Symptomatology–Self-report (QIDS-SR) and Dimensional Anhedonia Rating Scale (DARS);(week 6)
- psychotic symptoms as reflected by changes in Positive and Negative Symptoms Scale (PANSS scores)(week 6)
- sleep quality measured by Pittsburgh Sleep Quality Index (PSQI)(week 6)
- Subjective cognitive functioning will be assessed using the Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA) and Patient-Reported Outcomes Measurement Information System (PROMIS), and objective cognitive functioning as measured by Screen for Cognitive Impairment in Psychiatry (SCIP)(week 6)
- suicidal thoughts and behaviours as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)(week 0-6)
- Quality of life assessed using The Brief Quality of Life in Bipolar Disorder Questionnaire (Brief QoL-BD(week 6)
- Daily functioning based on Functioning Assessment Short Test (FAST)(Week 6)
- health services utilization by self-report(week 6)
- Open ended adverse report form and b) the Frequency, Intensity, Burden of Side Effects Rating scale (FIBSER)(week 6)
研究者
研究点 (4)
Loading locations...
相似试验
招募中
3 期
Cannabidiol for Bipolar Depression (CBD-BD)Bipolar DisorderNCT05867849University of British Columbia360
招募中
2 期
Cannabidiol as an add-on Treatment During Inpatient Alcohol Cessation : CBD-OH2024-518455-28-00Assistance Publique Hopitaux De Paris210
进行中（未招募）
3 期
A Double-Blind Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory EpilepsyEpilepsyNCT02783092Antonio Waldo Zuardi126
招募中
2 期
MIVetsCan: Cannabidiol (CBD)-Care TrialPain, ChronicNCT06213233Kevin Boehnke468
终止
2 期
Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg Vs Placebo As Adjuvant Treatment in Chronic Migraine -Chronic Migraine, HeadacheOveruse Headache MedicationNCT04989413Hospital Israelita Albert Einstein110